Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes

By Reuters News

- Eli Lilly and Company LLY.N:

  • ELI LILLY: PHASE 2 DATA SHOWED ELORATZP DELIVERED WEIGHT LOSS OF UP TO AVERAGE OF 54.1 LBS (23.3%) AT 48 WEEKS IN ADULTS WITH OBESITY, TYPE 2 DIABETES

  • ELI LILLY: ELORATZP LOWERED A1C BY UP TO AVERAGE OF 2.9%, WITH UP TO 77% OF PARTICIPANTS ACHIEVING NORMAL BLOOD SUGAR LEVELS

  • ELI LILLY: PHASE 3 SURMOUNT-ADOLESCENTS SHOWED ZEPBOUND REDUCED BMI BY AVERAGE OF 21.4% IN ADOLESCENTS AGED 12 TO <18 YEARS WITH OBESITY

Source text: [ID:]

Further company coverage: LLY.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.